Statements, Letters, and Regulatory Comments

Statements, Letters, and Regulatory Comments

By educating elected officials and other government decision-makers on the needs of the cystic fibrosis community, the Cystic Fibrosis Foundation works to shape public policy to help our efforts to cure CF and provide all people with CF the opportunity to live full, healthy lives. Below find a listing of our state and federal statements, letters, and regulatory comments.

Statements, letters, and regulatory comments issued before July 2023 can be found in our archive.
Prior Authorization CF Foundation Supports Alaska’s Efforts to Streamline the Prior Authorization Process

In a letter to Alaska's Health and Social Services Committee, the Cystic Fibrosis Foundation expressed its support to reduce the administrative burden and delays in care by establishing a gold carding provision that would exempt providers from prior authorization requirements if 90 percent of their requests were approved in the preceding 12 mont
Drug Pricing and Access | Prior Authorization CF Foundation Supports Illinois' Efforts to Cap Copays for Inhalers and Streamline Prior Authorization Requirements

In a letter to the Illinois House Health Care Availability & Accessibility Committee and the Illinois House Insurance Committee, the Cystic Fibrosis Foundation expressed support for two bills — HB 4504, which would limit copays for prescription inhalers, and HB 5051, which would prohibit prior authorization on long-term prescriptions.
Prior Authorization CF Foundation Supports Ohio Efforts to Simplify Prior Authorization Requirements

In a letter to the Ohio House Insurance Committee, the Cystic Fibrosis Foundation expressed its support of HB 130 to streamline prior authorization requirements and urged the committee to lower the gold carding threshold for prescribers.  
Drug Pricing and Access | Prior Authorization CF Foundation Supports Vermont Efforts to Reform Prior Authorization

In a letter to the Vermont House of Representatives, the Cystic Fibrosis Foundation expressed its support for H. 766, which, if passed, would make several important reforms to the prior authorization process and would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
Drug Pricing and Access | Prior Authorization CF Foundation Supports New Jersey’s Efforts to Reform Prior Authorization

The Cystic Fibrosis Foundation expressed support to the New Jersey General Assembly for A1255, Ensuring Transparency in Prior Authorization, which makes several important reforms to the prior authorization process.
Prior Authorization CF Foundation Supports District of Columbia’s Efforts to Reform Prior Authorizations

The CF Foundation expressed support to the Council of the District of Columbia for B25-0124, Prior Authorization Reform Amendment Act of 2023, which makes several important reforms to the prior authorization process.
Prior Authorization CF Foundation Thanks California Department of Health Care Services For Including Certain CF Medications in a List of Those Eligible for Extended Prior Authorization

CF Foundation letter thanking the California Department of Health Care Services for including certain CF medications on the state's list of medications eligible for extended duration prior authorization under Medi-Cal Rx and requesting the inclusion of additional medications to that list.